Ken Li ,Partner


    MBA from Babson College; MS in Chemistry from the City University of New York; BS in Pharmaceutical Sciences from West China Medical Center, Sichuan University

Work Experience

    Over 20 years of experience in pharmaceutical R&D, manufacturing, management and investment.

    Chairman, Sunforest Capital

    Managing Partner, Yuanming Capital

    Partner, Mingxin China Growth Fund

    China General Manager, Chiral Quest

    Senior Scientist, Eisai Research Institute

    Scientist, Wyeth

Investment Cases

    Enzymaster, Pharbers Genesis, Novaxelgen, InnoModels Bio, Readitec, United Imaging, CF PharmTech, Adlai Nortye, Sironax, Pharmacodia, Ascentage Pharma (06855.HK), Ansun, JW Therapeutics (02126.HK), Sonicmed, Yocaly Enterprise, Hengrui (600276), Innovent, Asymchem, Zai Lab (NASDAQ: ZLAB), BeiGene (688235), Porten (300363), SINQI (300573) and Tigermed (300347)